{"url_path":"/sec/cbio/10-q/2026/item-5","section_key":"item-5","section_title":"Item 5 Other Information","topic":"sec","document":{"doc_type":"10-Q/A","doc_date":"2026-06-22","source_url":"https://www.sec.gov/Archives/edgar/data/1253689/0001628280-26-044713-index.html","accession_number":"0001628280-26-044713","cik":"0001253689","ticker":"CBIO","issuer_name":"CRESCENT BIOPHARMA, INC.","edgar_url":"https://www.sec.gov/Archives/edgar/data/1253689/0001628280-26-044713-index.html","primary_entity_key":"0001253689","primary_entity_name":"CRESCENT BIOPHARMA, INC."},"word_count":298,"has_tables":true,"body_markdown":"Item 5. Other Information\n\n(a) None.\n\n(b) None.\n\n(c) Trading Arrangements    \n\nOn February 25, 2026, each of (i) Joshua Brumm, our Chief Executive Officer and member of the Company’s Board of Directors, (ii) Jonathan McNeill, our Chief Operating Officer and President, (iii) Ellie Im, our Chief Medical Officer, (iv) Jan Pinkas, our Chief Scientific Officer, (v) Richard Scalzo, our Chief Financial Officer, (vi) Ryan Lynch, our Treasurer, Senior Vice President of Finance and Chief Accounting Officer, and (vii) Barbara Bispham Hale, our General Counsel and Corporate Secretary, adopted a Rule 10b5-1 trading arrangement intended to satisfy the affirmative defense of Rule 10b5-1(c) authorizing the pre-arranged sale of ordinary shares in order to satisfy tax withholding obligations of the Company that arise in connection with the vesting of any restricted stock units and/or performance stock units granted to them under the Crescent Biopharma, Inc. 2025 Stock Incentive Plan, the Crescent Biopharma, Inc. 2025 Employment Inducement Incentive Award Plan and the Crescent Biopharma, Inc. 2024 Equity Incentive Plan, as amended, including under any successor plan and the related issuance of ordinary shares (each, a “Sell-to-Cover 10b5-1 Instruction”). The number of ordinary shares to be sold to satisfy the Company’s tax withholding obligations under each Sell-to-Cover 10b5-1 Instruction is not currently determinable. Each person’s Sell-to-Cover 10b5-1 Instruction will remain in effect so long as taxes are required to be paid upon the vesting or settlement of restricted stock units or performance stock units awarded or to be awarded to such person, unless such person’s instruction letter is earlier terminated.\n\nNo other director or \"officer\" (as defined in Rule 16a-1(f)) adopted or terminated any Rule 10b5-1 trading arrangement and/or non-Rule 10b5-1 trading arrangement (in each case, as defined in Item 408 of Regulation S-K) during the three months ended March 31, 2026."}